Patient Satisfaction And Visual Performance In Patients With Retinal Comorbidities Implanted With An Extended-Depth Of Focus Iol
Published 2023 - 41st Congress of the ESCRS
Reference: FP32.12 | Type: Free paper | DOI: 10.82333/8617-b715
Authors: Detlev Breyer* 1 , Lena Beckers 1 , Caridad Perez-Vives 2
1Breyer, Kaymak & Klabe Augenchirurgie,Düsseldorf,Germany, 2Alcon Vision LLC,Fort Worth, TX,United States
Purpose
To report patient satisfaction and visual performance outcomes in subjects with mild retinal comorbidities implanted bilaterally with AcrySof IQ Vivity or/and AcrySof IQ Vivity Toric IOL.
Setting
This is a sub-analysis of a multicenter, ambispective registry study conducted in Europe, Australia and New Zealand evaluating the performance of subjects with mild retinal comorbidities and bilaterally implanted with AcrySof IQ Vivity and/or AcrySof IQ Vivity Toric IOL in a real world setting through routine clinical practice.
Methods
After a minimum of 3 months and up to 6 months postoperative of the 2nd eye surgery, patient reported outcomes were recorded through validated questionnaires. Catquest SF-9 was used to evaluate patient’s satisfaction and grade the difficulty to see to perform daily activities and IOLSAT for spectacle independence at different distances. Visual disturbances were evaluated through a non-prompted interview and binocular uncorrected and distance corrected visual acuities at distance, intermediate (66 cm) and near (40 cm) were also measured (UCDVA/BCDVA, UCIVA/DCIVA and UCNVA/DCNVA). Retinal comorbidities included age-related macular degeneration (n=6) and retinopathy or maculopathy due to other causes (n=36).
Results
This subgroup includes 42 subjects with mild retinal comorbidities implanted with the AcrySof IQ Vivity IOL. More than 88% of the patients were satisfied with their sight and 71.4% reported no difficulty with their sight during everyday life. Most of the patients reported never/rarely using spectacles at near, intermediate and distance by 54.8%, 88.1% and 90.5%, respectively. Postoperative binocular mean logMAR (standard deviation) UCDVA was 0.048 (0.128), UCIVA 0.094 (0.120) and UCNVA 0.259 (0.156). Binocular BCDVA improved from 0.113 logMAR (0.112) preoperatively to 0.007 logMAR (0.118) postoperatively. Furthermore, 88.1%, 90.5% and 95.2% of subjects reported no halos, starbursts or glare, respectively.
Conclusions
The current data shows that patients with mild retinal comorbidities implanted with AcrySof IQ Vivity / AcrySof IQ Vivity Toric IOL EDOF had good visual performance with frequent spectacle independency at intermediate and far and little to no visual disturbances.